Vera Therapeutics

Compare

718 Followers

VERA Stock Chart & Stats

$28.46

-$0.18(-0.43%)

At close: Jan 08 4:00 PM EST

$28.46

-$0.18(-0.43%)

Day’s Range― - ―

52-Week Range$18.53 - $51.61

Previous CloseN/A

Volume142.65K

Average Volume (3M)1.47M

Market Cap

$1.99B

Enterprise Value$1.02B

Total Cash (Recent Filing)$556.83M

Total Debt (Recent Filing)$77.55M

Price to Earnings (P/E)―

Beta1.54

Next Earnings

Nov 05, 2025

EPS Estimate

-1.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.20

Shares Outstanding63,823,666

10 Day Avg. Volume1,120,971

30 Day Avg. Volume1,474,393

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.51

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.82K

Enterprise Value/Ebitda-4.71

Forecast

1Y Price Target

$73.00

Price Target Upside156.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe atacicept Ph3 ORIGIN3 study in IgAN met its interim primary endpoint, supporting accelerated approval.

Financial StabilityVera had cash and cash equivalents of approximately $557M, which is believed to be sufficient to fund operations in the foreseeable future.

Market PotentialAtacicept for IgAN is the largest single product driver with blockbuster potential and anticipated conditional marketing approval, representing a $15bn peak market where biologics command high pricing.

Bears Say

CompetitionOtsuka has filed a BLA for the accelerated approval of sibeprenlimab in IgAN, presenting competition for Vera Therapeutics.

Competitive RiskThe biggest risk to the Buy rating is the evolving clinical profiles of competitor BAFF/APRIL drugs being developed by well-capitalized sponsors.

Investor SentimentShort interest stands at 17.4% of the float, indicating a level of skepticism among investors.

Vera Therapeutics News

Vera Therapeutics initiated with a Buy at BofA

BofA initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $48 price target The firm sees...

19d ago

VERA

Vera Therapeutics Advances Atacicept Study in Autoimmune Kidney Diseases

Vera Therapeutics, Inc. (($VERA)) announced an update on their ongoing clinical study. Vera Therapeutics, Inc. is conducting a...

7d ago

VERA

Vera Therapeutics Advances IgAN Treatment with Atacicept Study

Vera Therapeutics, Inc. (($VERA)) announced an update on their ongoing clinical study. Vera Therapeutics, Inc. is conducting a...

7d ago

VERA

Vera Therapeutics Advances Atacicept Study for IgAN: Key Insights for Investors

Vera Therapeutics, Inc. (($VERA)) announced an update on their ongoing clinical study. Vera Therapeutics, Inc. is conducting a...

7d ago

VERA

Vera Therapeutics: Buy Rating Backed by Atacicept’s Promising Potential in IgA Nephropathy Treatment

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on VERA stock, giving a Buy rating on...

1M ago

VERA

Buy Rating Affirmed for Vera Therapeutics Amid Revised KDIGO Guidelines Boosting IgAN Treatment Market

LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VERA stock, giving a Buy rating yesterday....

2M ago

VERA

KDIGO guidelines positive for Vera Therapeutics, says Cantor Fitzgerald

Cantor Fitzgerald keeps an Overweight rating on Vera Therapeutics (VERA) with a $100 price target after non-profit Kidney...

2M ago

VERA

Vera Therapeutics Reports Progress in Clinical Trials

Vera Therapeutics, Inc. ( ($VERA) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

VERA

Vera Therapeutics Signs New Sales Agreement with TD Securities

Vera Therapeutics ( ($VERA) ) has shared an announcement. On August 5, 2025, Vera Therapeutics entered into a...

3M ago

VERA

Vera Therapeutics reports Q2 EPS ($1.20), consensus (62c)

“Our team delivered exciting new clinical results from our pivotal ORIGIN 3 trial in the second quarter of...

3M ago

VERA

Vera Therapeutics announces anticipated upcoming milestones

Submission of a BLA for atacicept in IgAN to the U.S. FDA in Q4 2025 for accelerated approval;...

3M ago

VERA

Vera Therapeutics sees cash funding operations through launch of atacicept

Vera reported $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which combined...

3M ago

VERA

Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz

The major averages were sharply higher near noon, rebounding from Friday’s losses as traders begin to price in...

3M ago

Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

AVB

BAX

VERA FAQ

What was Vera Therapeutics’s price range in the past 12 months?

Vera Therapeutics lowest stock price was $18.53 and its highest was $51.61 in the past 12 months.

What is Vera Therapeutics’s market cap?

Vera Therapeutics’s market cap is $1.99B.

When is Vera Therapeutics’s upcoming earnings report date?

Vera Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is tomorrow.

How were Vera Therapeutics’s earnings last quarter?

Vera Therapeutics released its earnings results on Aug 05, 2025. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.378.

Is Vera Therapeutics overvalued?

According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vera Therapeutics pay dividends?

Vera Therapeutics does not currently pay dividends.

What is Vera Therapeutics’s EPS estimate?

Vera Therapeutics’s EPS estimate is -1.16.

How many shares outstanding does Vera Therapeutics have?

Vera Therapeutics has 63,823,666 shares outstanding.

What happened to Vera Therapeutics’s price movement after its last earnings report?

Vera Therapeutics reported an EPS of -$1.2 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 0.929%.

Which hedge fund is a major shareholder of Vera Therapeutics?

Currently, no hedge funds are holding shares in VERA

Vera Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-54.83%

Trailing 12-Months

Asset Growth

45.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vera Therapeutics

Vera Therapeutics (VERA) is a biotechnology company focused on developing transformative treatments for serious immunological diseases. With a strong emphasis on research and development, the company's core product pipeline includes innovative therapies aimed at addressing unmet needs in the treatment of kidney diseases and other immune-related conditions.

Vera Therapeutics (VERA) Earnings & Revenues

Historic Earnings Reports

VERA Stock 12 Month Forecast

Average Price Target

$73.00

▲(156.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","60":"$60","101":"$101","39.5":"$39.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$73.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,39.5,60,80.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.79,34.26769230769231,39.745384615384616,45.223076923076924,50.70076923076923,56.17846153846154,61.65615384615385,67.13384615384615,72.61153846153846,78.08923076923077,83.56692307692308,89.04461538461538,94.52230769230769,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.79,32.19076923076923,35.59153846153846,38.99230769230769,42.39307692307692,45.793846153846154,49.19461538461538,52.59538461538462,55.996153846153845,59.39692307692307,62.79769230769231,66.19846153846154,69.59923076923076,{"y":73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.79,30.267692307692307,31.745384615384616,33.223076923076924,34.70076923076923,36.17846153846154,37.65615384615384,39.13384615384615,40.61153846153846,42.08923076923077,43.566923076923075,45.04461538461538,46.52230769230769,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >